Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)

Market Cap	5.16B +48.5%
Revenue (ttm)	1.21B +22.5%
Net Income	92.73M +579.3%
EPS	0.18 +500.0%
Shares Out	562.87M
PE Ratio	50.89
Forward PE	n/a
Dividend	0.05 (0.55%)
Ex-Dividend Date	n/a

Volume	33,232,709
Average Volume	26,666,709
Open	9.51
Previous Close	9.16
Day's Range	9.30 - 9.69
52-Week Range	6.13 - 11.98
Beta	0.49
RSI	45.79
Earnings Date	Apr 22, 2026

About SHE:300016

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride and repaglinide tablets and jiuwei zhenxin granules. It also offers gadolinium-based agents, including gadopentetate dimeglumine and gadobutrol, as wel...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,173
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300016

Financial Performance

In 2025, SHE:300016's revenue was 1.21 billion, an increase of 22.54% compared to the previous year's 983.55 million. Earnings were 92.73 million, an increase of 579.29%.